Programme as pdf for download | |
TUESDAY, APRIL 23, 2013 | |
09:00 | Registration |
09:30 | Welcome and Opening |
09:45 | Keynote Lecture IgM - the past and the present N.H. Teng, Stanford University, School of Medicine, CA/USA |
IgM - BASIC SCIENCE, ISOLATION | |
10:15 | Competitive binding of GRP78 and LDL to the anti-cancer monoclonal IgM PAT-SM6 Z. Rosenes, Y.F. Mok, T.D. Mulhern, D.M. Hatters, G.J. Howlett, University of Melbourne/AUS |
10:45 | Short presentation: A method for in vitro generation of diagnostic and therapeutically antibodies K. Müller-Zahm, S. Thiele, D. Paul, P. Miethe, FZMB GmbH, Bad Langensalza/D |
11:00 | Coffee break |
11:30 |
Production of different IgM glycoforms in Nicotiana benthamiana |
12:00 |
IgG to IgM class switch: modification of protein properties by antibody engineering |
12:30 |
Generation of antibodies targeting cell surface antigens on ovarian cancer cells |
13:00 |
Lunch, followed by coffee break and exhibition |
|
UPSTREAM / DOWNSTREAM DEVELOPMENT |
14:00 | A rapid one-step hydroxyapatite method to obtain highly purified monoclonal IgM for research use X. He, Bio-Rad Laboratories, Hercules, CA/USA; T. Gan, S. Latiff, W. Lau, P. Gagnon, Bioprocessing Technology Institute, Singapore/SGP |
14:30 |
The preparative purification and analysis of immunoglobulin M utilizing ion exchange and affinity chromatography with a novel affinity ligand immobilized on a robust high throughput resin C. Gebski, P. Lynch, Life Technologies, Bedford, MA/USA |
15:00 | HPLC method for quantitative determination of CHO-cell recombinant monoclonal IgM antibody M. Zorz, S. Peljhan, M. Barut, A. Strancar, BIA Separations d.o.o., Ajdovscina/SLO; R. Weik, H. Katinger, Polymun Scientific GmbH, Klosterneuburg/A |
15:30 |
Coffee break |
16:00 | Characterization and evaluation of potential IgM capture matrices J. Schreffler, E. Wiltsie, Morphotek, Inc., Exton, PA/USA |
16:30 |
Exclusively monolithic purification of clinical grade IgM monoclonal antibodies P. Gagnon, H.T. Gan, J . Lee, S.M. Abdul Latiff, C. Chuah, Bioprocessing Technology Institute, Singapore/SGP |
17:00 - 17:30 |
Stability of IgMs at low pH used during purification and during storage M. Müller, University of Vienna/A and, Bioprocessing Technology Institute, Singapore/SGP; M. Loh, Bioprocessing Technology Institute, Singapore/SGP; A. Jungbauer, University of Natural Resources and Applied Life Sciences/A; M. Bardor, P. Gagnon, Bioprocessing Technology Institute, Singapore/SGP |
19:00 |
Get-Together - to be announced onsite |
WEDNESDAY, APRIL 24, 2013 | |
UPSTREAM / DOWNSTREAM DEVELOPMENT | |
09:00 | Efficient inactivation of small non-enveloped viruses in IgM processes A. Meyer, Sartorius Stedim Biotech GmbH, Göttingen/D |
09:30 |
Development of a second-generation downstream process for an IgM therapeutic |
10:00 | Improving robustness and safety of a downstream process for IgM J. Abildskov, S. Bergmann, CMC Biologics A/S, Copenhagen/DK |
10:30 | Coffee break |
11:00 |
Manufacture of recombinant IgM-antibodies - a case study |
11:30 |
Analytical methods to support IgM development and manufacturing |
12:00 | Special lecture IP protection strategies - from ideas to patents R. Seifert, Patentquadrat, Martinsried/D |
CLINICAL DEVELOPMENT | |
12:30 |
The birth pangs ofmonoclonal antibody therapeutics |
13:00 |
Lunch, followed by coffee break and exhibition |
14:00 |
Preclinical investigations of natural regulatory antibodies to apoptotic cells |
14:30 |
10 years follow-up of a prospective trial for targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1 |
15:00 | Does a "thiol shield" protect tumors from natural IgM antibody, and, if so, how can it be suppressed? P. Jones, John Wayne Cancer Institute, Los Angeles, CA/USA |
15:30 | Coffee break |
16:00 | Natural human autoreactive IgMs as therapeutics for neurologic disease: from discovery, to recombinant, to trial A.E. Warrington, M. Rodriguez, Mayo Clinic, Rochester, MN/USA |
16:30 | Pre-clinical and early clinical development of human IgM antibody PAT-SM6 V. Dubljevic, Patrys Ltd., Melbourne/AUS; L. Rasche, Universitätsklinikum Würzburg/D; S. Braendlein, University Hospital, University of Würzburg/D; F. Hensel, Patrys GmbH, Würzburg/D |
17:00 |
Harnessing therapeutic potential of natural IgM: Is it about time? |
17:30 | End of the workshop |